Oracle’s Rebound Is All But Assured So I Keep Buying

Photo of Alex Sirois
By Alex Sirois Published

Quick Read

  • ORCL shares are down 40% over the past year while signed contracts hit $638 billion, up 363% year over year.

  • Oracle's 72 Multicloud datacenters embedded inside MSFT and AMZN clouds let it collect revenue regardless of which hyperscaler wins a workload.

  • Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Oracle didn't make the cut. Grab the names FREE today.

Oracle’s Rebound Is All But Assured So I Keep Buying

© JasonDoiy / Getty Images

I keep hitting the buy button on Oracle (NYSE:ORCL | ORCL Price Prediction), and the reason is embarrassingly simple: I have never seen a book of business this large sitting under a stock this beaten up. Shares closed at $147.02 on August 7, down 40.37% over the past year and 33.43% below where they sat the day of the Q2 revenue miss last December. Meanwhile the contracted backlog just went vertical.

The Core Thesis: A Backlog That Underwrites the Guidance

Oracle closed Q4 FY2026 with $638 billion in Remaining Performance Obligations, up 363% year over year. These are binding, multi-year enterprise contracts, largely driven by compute-hungry AI workloads including multi-billion dollar commitments from OpenAI, Meta, and xAI. Roughly $76 billion, or 12%, converts to top-line revenue over the next 12 months, effectively pre-funding next year’s guidance before a single new deal is signed. CFO Hilary Maxson told analysts the RPO “provides exceptional visibility into our future revenue growth”. That is the sentence I keep coming back to.

The Data Case

Three receipts. First, growth is real and it is in the right place. Cloud Infrastructure grew 93% year over year to $5.787 billion, and total cloud revenue is now 52% of quarterly sales, up from 43% a year ago. Q1 FY2027 guidance calls for cloud revenue growth of 58% to 64%.

Second, the valuation is reasonable on its own terms. The forward P/E sits at 18, the PEG ratio is 0.831, and management reconfirmed a 31% revenue CAGR and 28% EPS CAGR through fiscal year 2030. FY2027 non-GAAP EPS is guided to $8.05.

Third, the checks keep coming. The quarterly cash dividend is $0.50 per share, and operating cash flow for the year was $32 billion, up 54%. Return on equity is 53.4%.

Why Not the Hyperscalers

The obvious alternatives are Microsoft (NASDAQ:MSFT), Amazon (NASDAQ:AMZN), and Alphabet (NASDAQ:GOOGL). I own some of those too. But Oracle is running a strategy the others cannot copy: it is building 72 Oracle Multicloud datacenters embedded inside Amazon, Google, and Microsoft clouds. Oracle collects whichever hyperscaler wins the workload. The Multicloud AI Database business grew 404% in Q4. I do not need to guess the winner at a PEG of 0.831.

The Real Risk

Free cash flow was negative $23.686 billion against CapEx of $55.663 billion, and total liabilities sit at $218.703 billion. Retail investors are also nervous about the 346 million Oracle shares Larry Ellison has pledged as loan collateral. Both are real. What holds my thesis together is that $75 billion of the RPO is either bring-your-own-hardware or prepaid, meaning customers front the capital. Management pegs steady-state ROIC on infrastructure projects in the high 20s. That is a company being paid to build, with customers fronting the capital.

Forward Conviction

Analysts covering the name carry a consensus target of $247.17, with 37 of 44 rating it Buy or Strong Buy. For this thesis to work, $638 billion in signed contracts needs to convert to revenue on schedule, and I am being paid a dividend to wait. The buy button stays active.

Contact [email protected] for any questions or corrections.

Photo of Alex Sirois
About the Author Alex Sirois →

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.

Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.

At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

Continue Reading

Top Gaining Stocks

ABNB Vol: 15,913,532
MCHP Vol: 19,139,274
PLTR Vol: 77,244,625
MRNA Vol: 6,820,582
AXON Vol: 1,591,869

Top Losing Stocks

TTD Vol: 133,458,224
CTRA Vol: 73,319,495
AKAM Vol: 8,143,961
ZTS Vol: 12,784,553
RMD Vol: 3,810,438